Pharmaceutical Assessor @ (March 2022 - February 2024)
Scientific Adviser @ (May 2020 - October 2021)
Pharmacokinetics Assessor @ (August 2018 - May 2020)
Biopharmaceutics Strategist @ (October 2015 - September 2018)
Acting Scientific Director for Pharmaceutics and Biotechnology @ (January 2013 - October 2015)
Biopharmaceutics Strategist @ (September 2012 - December 2012)
Associate Principal Scientist, biopharmaceutics @ (September 2004 - September 2012)
Pharmaceutical Assessor @ (September 2002 - September 2004)
Associate Principal Scientist, Biopharmaceutics @ (May 2000 - September 2002)
Senior Scientist, Biopharmaceutics @ (March 1999 - May 2000)
PhD student, Biopharmaceutics and Pharmacokinetics @ (January 1993 - January 1999)
Pharmacist @ (September 1991 - September 1993)
Anders Lindahl Education
Uppsala universitet
PhD (Biopharmaceutics)
1993-1999
Uppsala universitet
Master of Science (M.Sc.) (Pharmaceutics)
1986-1990
Anders Lindahl Skills
Biopharmaceutics
Gastro Plus
Formulation Development
In Vivo
Pharmaceutical Research
Clinical Pharmacology
Drug Metabolism
Biotechnology
Life Sciences
Validation
ADME
Quality by Design
DMPK
Drug Discovery
Drug Delivery
Pharmaceutical Development
Pharmaceutics
Drug Development
Clinical Development
Bioequivalence
In Vitro
Pharmacodynamics
Regulatory Submissions
Pharmacology
Formulation
CMC
Product Development
Pharmaceutical Industry
GLP
Ivivc
Pharmacokinetics
Anders Lindahl Summary
Anders Lindahl, based in Uppsala, SE, is currently a Scientific Director, Pharmaceutics at Medical Products Agency Läkemedelsverket. Anders Lindahl brings experience from previous roles at Medical Products Agency Läkemedelsverket, Catalent Pharma Solutions and Läkemedelsverket. Anders Lindahl holds a 1993 - 1999 PhD in Biopharmaceutics @ Uppsala universitet. With a robust skill set that includes Biopharmaceutics, Gastro Plus, Formulation Development, In Vivo, Pharmaceutical Research and more. Anders Lindahl has 1 emails on RocketReach.
Looking for a different Anders Lindahl?
Find contact details for 700 million professionals.